CA-LASERFICHE
New research by Medical Group Management Association (MGMA) and Laserfiche — the leading SaaS provider of intelligent content management and business process automation — reveals that most healthcare organizations’ top priorities when considering integrative technologies are the elimination of manual work, mitigation of clinician/worker burnout and time savings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128977000/en/
Discover the opportunities and challenges for medical practice leaders in evaluating their platforms for workflow, electronic forms, document and records management and more. (Graphic: Business Wire)
“The healthcare industry has been disrupted by the growth of virtual visits, expectations for more personal, faster access to patients’ clinical results and care, plus the rise of AI,” said Grace Nam, strategic solutions manager, healthcare, at Laserfiche. “These trends have created a burgeoning challenge of managing, processing and leveraging an inundation of data that require cross-functional collaboration, and often include external organizations like labs and other physicians.”
The study surveyed medical practice administrators, physicians, billing and coding leaders and health information technology (HIT) workers for their views on electronic health records (EHR) or practice management (PM) systems, business automation and more. According to the report, most healthcare organizations are not looking to make a switch to a new EHR or PM system and nearly 80% of respondents rated their current EHR system as “very good” or “good.” However, when it came time to rate EHR systems’ individual attributes, those ratings dropped. Only half of respondents rated their EHR systems “very good” or “good” at saving time; 47% said they were very good or good at saving money; and only 40% said they were very good or good at mitigating clinician/worker burnout.
“Time-strapped organizations need integrated technologies to extract value from data without adding to the long list of manual tasks for already overwhelmed employees,” Nam added. “Investments in systems that enable business process automation while facilitating information governance are critical to healthcare organizations’ ability to leverage data and retain employees while providing a modern patient experience. Supporting the back office — including medical billing and coding, and working with third-party insurance companies — to boost speed and accuracy will be critical for on-time payments that impact revenue.”
“The business of healthcare and its future are tied directly to the ability to manage and make decisions based on data to support high-quality patient care,” the report states. “As the amount of data generated in healthcare grows about 47% a year, the need to manage the growing volumes of records in a secure, compliant fashion is unmistakable.”
To download a copy of the Intelligent Automation in Healthcare report, visit https://info.laserfiche.com/resource/intelligent-automation-healthcare.
To learn more about Laserfiche solutions for the healthcare industry, visit laserfiche.com/solutions/healthcare.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through workflows, e-forms, document management, integrations and analytics, the Laserfiche® platform centralizes information, structures clinical data and streamlines back-office processes so that healthcare professionals can focus on providing the highest standard of patient care.
For over 30 years, Laserfiche has served organizations in the healthcare industry as a trusted system for document and records management, enabling medical professionals to quickly retrieve records when needed, with robust security and compliance tools to support HIPAA compliance and patient confidentiality. By streamlining paperwork, information and data using digital forms and automated workflows, Laserfiche allows administration, clinicians and physicians to eliminate repetitive manual tasks, gain visibility into operations, support a holistic approach to patient care and focus on improving patient outcomes. Prebuilt solutions and integrations with industry-specific and common business applications further extend organizations’ digital transformation initiatives.
Today, Laserfiche’s cloud-first approach incorporates innovations in machine learning and AI, supporting healthcare organizations in empowering staff, streamlining the patient experience, supporting HIPAA compliance and providing the best possible patient experience.
Learn more at laserfiche.com/solutions/healthcare.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231128977000/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom